Bradley A. Keywell Sells 265,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Tempus AI Stock Up 1.2 %

NASDAQ:TEM opened at $35.15 on Monday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s 50-day moving average price is $46.03 and its 200-day moving average price is $47.27.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEM. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Loop Capital cut their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $56.36.

Institutional Trading of Tempus AI

Several institutional investors have recently bought and sold shares of the business. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the 3rd quarter valued at approximately $30,000. Geode Capital Management LLC lifted its holdings in Tempus AI by 0.4% during the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after purchasing an additional 539 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at about $67,000. Vestor Capital LLC purchased a new stake in shares of Tempus AI during the third quarter worth about $153,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after purchasing an additional 2,765 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.